DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced that Arthur T. Suckow, Ph.D., Chief Executive Officer, will be presenting a company overview and participating in virtual one-on-one meetings along with Denise Bevers, Chief Operating Officer, at the 2021 Biotech Showcase from January 11th – 15th.
Recommended AI News: Sesame Software Announces Fully Automated Connectors to Accelerate Data Loading Into Amazon Redshift
To schedule a meeting with the DTx management team at this conference, please visit the Biotech Showcase partnering system or contact DTx at info@dtxpharma.com.
Recommended AI News: Current Becomes First Fintech to Receive Government Stimulus Payments
DTx Pharma, Inc. is a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease. The company’s proprietary delivery technology platform, FALCON (Fatty Acid Long Chain OligoNucleotide), utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body. In preclinical studies, DTx has demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells and many other specialized cell types. Based upon the novelty, IP position and data demonstrating the effectiveness of its proprietary fatty acid motifs, DTx has previously received investment, nondilutive funding and other forms of support from Eli Lilly, Eye CRO and the CMT Research Foundation (CMTRF) for its ocular and muscle programs and has received multiple grant awards from the NIH (NCATS, NIA), and the TPEP program of Alzheimer’s Association and Rainwater Charitable Trust to advance its efforts to treat CNS diseases.
Recommended AI News: Contentsquare Appoints Travis Burke as Global VP of Corporate Development
